newregime
good luck see below plus obj are talking to others but best is go to the obj announ and read as many as u can to get the feel for the company also if u have the time the asx site under announ if u wanted to know from past years some relevant stuff there as obj has being working on this for a long time
Wednesday, 4 November 2009
OBJ ENTERS INTO MATERIALS TRANSFER AGREEMENT
OBJ (ASX: OBJ) wishes to advise shareholders that it has entered into a Materials
Transfer Agreement (MTA) with 3M Corporation of St Paul, Minnesota USA, for the
evaluation of the Company’s eM‐patch® technologies as an approach to enhance
transdermal drug delivery. 3M is an American multinational corporation with 79,000
employees operating in 60 countries generating global sales in excess of US$25
billion in 2008. The evaluation will be conducted by the 3M Drug Delivery Systems
division which has been a leader in drug delivery for more than 50 years and has
extensive expertise in toxicology, regulatory, manufacturing, quality assurance and
operations.
The Materials Transfer Agreement sets the parameters for an initial in vitro testing
program to evaluate the performance of the eM‐patch® technology in conjunction
with 3M drug delivery platforms and proprietary formulations. The evaluation
program is expected to be completed by 1st February 2010.
About OBJ Ltd
OBJ Ltd is an early stage drug and cosmetic delivery company focused on the
development and commercialization of transdermal and transmembrane patches
and applicator technologies. OBJ develops low‐cost, high‐performance patch and
applicator products and undertakes partner funded developments using the
Company's dermaportation and eM‐patch® technologies. OBJ’s business focus is the
development of new products for supply or licencing and providing feasibility
assessments, patch formulations, testing and intellectual property development
services to partner companies.
About OBJ's Technologies
OBJ's proprietary technologies utilise magnetic field and magnetic array processes to
enhance the delivery of therapeutic and beneficial compounds. OBJ's technologies
have been shown in multi‐centred university studies and independent commercial
evaluations to enhance transdermal drug delivery of a wide a wide range of
commercially significant drugs and peptides.
- Forums
- ASX - By Stock
- WFL
- what have i missed
what have i missed, page-41
Featured News
Add WFL (ASX) to my watchlist
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable